193 related articles for article (PubMed ID: 38527005)
1. Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation.
Jeng-Miller KW; Miller MA; Heier JS
Oncologist; 2024 May; 29(5):e616-e621. PubMed ID: 38527005
[TBL] [Abstract][Full Text] [Related]
2. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS.
Méndez-Martínez S; Calvo P; Ruiz-Moreno O; Pardiñas Barón N; Leciñena Bueno J; Gil Ruiz MDR; Pablo L
Retina; 2019 Aug; 39(8):1435-1450. PubMed ID: 30681641
[TBL] [Abstract][Full Text] [Related]
3. Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Niro A; Strippoli S; Alessio G; Sborgia L; Recchimurzo N; Guida M
Am J Ophthalmol; 2015 Nov; 160(5):959-967.e1. PubMed ID: 26231307
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy.
Booth AEC; Hopkins AM; Rowland A; Kichenadasse G; Smith JR; Sorich MJ
Ther Adv Med Oncol; 2020; 12():1758835920944359. PubMed ID: 32821295
[TBL] [Abstract][Full Text] [Related]
5. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer.
McCannel TA; Chmielowski B; Finn RS; Goldman J; Ribas A; Wainberg ZA; McCannel CA
JAMA Ophthalmol; 2014 Aug; 132(8):1005-9. PubMed ID: 24852144
[TBL] [Abstract][Full Text] [Related]
6. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
Mettler C; Monnet D; Kramkimel N; Tréluyer JM; Mouthon L; Brézin A; Dupin N; Valnet-Rabier MB; Chouchana L; Terrier B
Ophthalmology; 2021 Dec; 128(12):1748-1755. PubMed ID: 34000304
[TBL] [Abstract][Full Text] [Related]
7. New features in MEK retinopathy.
Tyagi P; Santiago C
BMC Ophthalmol; 2018 Sep; 18(Suppl 1):221. PubMed ID: 30255823
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
Urner-Bloch U; Urner M; Jaberg-Bentele N; Frauchiger AL; Dummer R; Goldinger SM
Eur J Cancer; 2016 Sep; 65():130-8. PubMed ID: 27497344
[TBL] [Abstract][Full Text] [Related]
9. Transient MEK inhibitor-associated retinopathy in metastatic melanoma.
Urner-Bloch U; Urner M; Stieger P; Galliker N; Winterton N; Zubel A; Moutouh-de Parseval L; Dummer R; Goldinger SM
Ann Oncol; 2014 Jul; 25(7):1437-1441. PubMed ID: 24864047
[TBL] [Abstract][Full Text] [Related]
10. Ocular toxicities of MEK inhibitors and other targeted therapies.
Stjepanovic N; Velazquez-Martin JP; Bedard PL
Ann Oncol; 2016 Jun; 27(6):998-1005. PubMed ID: 26951625
[TBL] [Abstract][Full Text] [Related]
11. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
12. Mitogen-activated protein kinase inhibitor-associated retinopathy (MEKAR). A clinical case.
Buenasmañanas-Maeso M; Gutiérrez-Montero Ó; Reche-Sainz JA; Badillo Arcones E; Monja-Alarcón N; Toledano-Fernández N
Arch Soc Esp Oftalmol (Engl Ed); 2022 May; 97(5):286-289. PubMed ID: 35526952
[TBL] [Abstract][Full Text] [Related]
13. Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Han J; Chen J; Zhou H; Hao L; Wang Q
Oncology (Williston Park); 2023 Mar; 37(3):130-141. PubMed ID: 36961957
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.
Duncan KE; Chang LY; Patronas M
Eye (Lond); 2015 Aug; 29(8):1003-12. PubMed ID: 26043707
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment.
Kim YJ; Lee JS; Lee J; Lee SC; Kim TI; Byeon SH; Lee CS
Cancer Immunol Immunother; 2020 Dec; 69(12):2441-2452. PubMed ID: 32556494
[TBL] [Abstract][Full Text] [Related]
16. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
17. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
18. Ocular toxicities of fibroblast growth factor receptor inhibitors: A review.
Hsu J; Francis JH; Ahmad S
Surv Ophthalmol; 2024; 69(1):34-41. PubMed ID: 37777119
[TBL] [Abstract][Full Text] [Related]
19. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.
van der Noll R; Leijen S; Neuteboom GH; Beijnen JH; Schellens JH
Cancer Treat Rev; 2013 Oct; 39(6):664-72. PubMed ID: 23434072
[TBL] [Abstract][Full Text] [Related]
20. Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib.
Gavric AU; Ocvirk J; Mekjavic PJ
Radiol Oncol; 2018 Jun; 52(2):213-219. PubMed ID: 30018526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
